Innate Pharma SA announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial, evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma and Relapsed/Refractory Light-chain Amyloidosis 1.
Innate Pharma SA announced that the first patient was dosed in a Sanofi-sponsored Phase 1/2 clinical trial, evaluating SAR’514 / IPH6401 in relapsed/refractory Multiple Myeloma and Relapsed/Refractory Light-chain Amyloidosis 1.